Abstract
Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.
Keywords: Urothelial cancer, bladder cancer, chemotherapy, systemic therapy
Current Drug Therapy
Title: Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Volume: 5 Issue: 1
Author(s): Simon J. Crabb and Matthew Wheater
Affiliation:
Keywords: Urothelial cancer, bladder cancer, chemotherapy, systemic therapy
Abstract: Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.
Export Options
About this article
Cite this article as:
Crabb J. Simon and Wheater Matthew, Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010017
DOI https://dx.doi.org/10.2174/1574885511005010017 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Prostate Cancer Imaging: A New Era in Diagnostic Approach
Recent Patents and Topics on Imaging (Discontinued) Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Synthesis and Evaluation of Novel Erucin Analogues as Potential Antitumor Compounds
Letters in Organic Chemistry Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy Newer Approaches to the Discovery of Glitazones
Mini-Reviews in Organic Chemistry Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Synthesis and Antitumor Evaluation of Novel N-substituted Norcantharidin Imidazolium Derivatives
Current Organic Synthesis Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry